One of the selected review articles by Packer (2023) showed that, according to large-scale clinical trials, sodium-glucose cotransporter-2 (SGLT-2) inhibitors have the potential to effectively increase hemoglobin and hematocrit in patients with CKD-associated anemia. This evidence concerns the gene SLC5A2 and chronic kidney disease.